Capricor Presented Data On Allogeneic Cell-Derived Therapies At Gordon Research Conference

Schematic representation of exosome biogenesis. Source: Figure 1, de la Torre Gomez C, Goreham RV, Bech Serra JJ, Nann T and Kussmann M (2018) “Exosomics”—A Review of Biophysics, Biology and Biochemistry of Exosomes With a Focus on Human Breast Milk. Front. Genet. 9:92. doi: 10.3389/fgene.2018.00092, no changes made, Copyright © 2018 de la Torre Gomez, Goreham, Bech Serra, Nann and Kussmann,  distributed under the terms of the Creative Commons Attribution License (CC BY).
Advertisement img

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, founded in 2005, based in Los Angeles, focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.

Gordon Research Conferences are a group of prestigious international scientific conferences that are at the forefront of research in the biological, chemical and physical sciences and their related technologies.

The Gordon Research Conference on Extracellular Vesicles is focused on cutting-edge research on the biogenesis, molecular composition, functions, physio-pathological roles and potential clinical applications of extracellular vesicles.

Featured Partners

Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles. The company’s CAP-2003 therapy candidate is comprised of proprietary extracellular vesicles, including exosomes, which are generated from cardiosphere-derived cells (CDC-EVs). Capricor is developing CAP-2003 as a therapeutic platform for treating diseases involving inflammation and fibrosis.

Capricor recently presented research findings on the mechanism of action and the immunomodulatory capacities of CAP-2003 at the Gordon Research Conference on Extracellular Vesicles in Newry, Maine. The two posters presented at the Gordon Conference will be available on the Events & Presentations section of Capricor’s website.

Capricor is now conducting HOPE-2, a Phase II, randomized, double-blind, placebo-controlled study of repeat doses of CAP-1002 delivered intravenously in boys and young men with advanced stages of Duchenne muscular dystrophy.

“The pre-clinical studies presented at the Gordon Research Conference further elucidate Capricor’s progress in developing this exciting new class of therapeutics, the exosomes which comprise our investigational therapy, CAP-2003,” … “The studies further demonstrate that exosomes may be the active pharmaceutical ingredient (API) in CAP-1002, our cell therapy product, because these extracellular vesicles serve as cellular-messengers, altering function and physiology to balance inflammation so that cellular repair can be facilitated.” – Linda Marbán, Ph.D., Capricor chief executive officer